The FDA’s Center for Drug Evaluation and Research (CDER)’s Office of Compliance has implemented a new meeting for generic drug manufacturers that have received CGMP warning letters, offering a new avenue for a facility to obtain feedback on its remediation of warning letter deficiencies. As part of user fee negotiations under the Generic Drug User […]